Skip to main content

Select Committee written evidence reported in the House of Commons on Monday, 29 June 2026 from the Committee of Public Accounts.


Correspondence from the Parliamentary Under-Secretary of State for Public Health and Prevention relating to a contingent liability in respect of the provision and use of Favipiravir


Secondary information

Type
Parliamentary committee
Session
2026-27
Witnesses
Sharon Hodgson
Department of Health and Social Care
Subjects
Liability Japan Medical treatments Hantavirus Favipiravir
Contains statistics
Yes
Link
View this Parliamentary committee on committees.parliament.uk